Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.

Oncogene

Cherif C, Nguyen DT, Paris C, Le TK, Sefiane T, Carbuccia N, Finetti P, Chaffanet M, Kaoutari AE, Vernerey J, Fazli L, Gleave M, Manai M, Barthélémy P, Birnbaum D, Bertucci F, Taïeb D, Rocchi P.
PMID: 34711954
Oncogene. 2022 Jan;41(1):125-137. doi: 10.1038/s41388-021-02039-2. Epub 2021 Oct 28.

Disease progression and therapeutic resistance of prostate cancer (PC) are linked to multiple molecular events that promote survival and plasticity. We previously showed that heat shock protein 27 (HSP27) acted as a driver of castration-resistant phenotype (CRPC) and developed...

Cite
Cherif C, Nguyen DT, Paris C, et al. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene. 2021;41(1):125-137doi: 10.1038/s41388-021-02039-2.
Cherif, C., Nguyen, D. T., Paris, C., Le, T. K., Sefiane, T., Carbuccia, N., Finetti, P., Chaffanet, M., Kaoutari, A. E., Vernerey, J., Fazli, L., Gleave, M., Manai, M., Barthélémy, P., Birnbaum, D., Bertucci, F., Taïeb, D., & Rocchi, P. (2022). Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 41(1), 125-137. https://doi.org/10.1038/s41388-021-02039-2
Cherif, Chaïma, et al. "Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity." Oncogene vol. 41,1 (2022): 125-137. doi: https://doi.org/10.1038/s41388-021-02039-2
Cherif C, Nguyen DT, Paris C, Le TK, Sefiane T, Carbuccia N, Finetti P, Chaffanet M, Kaoutari AE, Vernerey J, Fazli L, Gleave M, Manai M, Barthélémy P, Birnbaum D, Bertucci F, Taïeb D, Rocchi P. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene. 2022 Jan;41(1):125-137. doi: 10.1038/s41388-021-02039-2. Epub 2021 Oct 28. PMID: 34711954.
Copy Download .nbib Format: NLM
Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.

Oncogene

Cherif C, Nguyen DT, Paris C, Le TK, Sefiane T, Carbuccia N, Finetti P, Chaffanet M, Kaoutari AE, Vernerey J, Fazli L, Gleave M, Manai M, Barthélémy P, Birnbaum D, Bertucci F, Taïeb D, Rocchi P.
PMID: 34711954
Oncogene. 2021 Oct 28; doi: 10.1038/s41388-021-02039-2. Epub 2021 Oct 28.

Disease progression and therapeutic resistance of prostate cancer (PC) are linked to multiple molecular events that promote survival and plasticity. We previously showed that heat shock protein 27 (HSP27) acted as a driver of castration-resistant phenotype (CRPC) and developed...

Cite
Cherif C, Nguyen DT, Paris C, et al. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene. 2021;doi: 10.1038/s41388-021-02039-2.
Cherif, C., Nguyen, D. T., Paris, C., Le, T. K., Sefiane, T., Carbuccia, N., Finetti, P., Chaffanet, M., Kaoutari, A. E., Vernerey, J., Fazli, L., Gleave, M., Manai, M., Barthélémy, P., Birnbaum, D., Bertucci, F., Taïeb, D., & Rocchi, P. (2021). Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, . https://doi.org/10.1038/s41388-021-02039-2
Cherif, Chaïma, et al. "Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity." Oncogene vol. (2021). doi: https://doi.org/10.1038/s41388-021-02039-2
Cherif C, Nguyen DT, Paris C, Le TK, Sefiane T, Carbuccia N, Finetti P, Chaffanet M, Kaoutari AE, Vernerey J, Fazli L, Gleave M, Manai M, Barthélémy P, Birnbaum D, Bertucci F, Taïeb D, Rocchi P. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene. 2021 Oct 28; doi: 10.1038/s41388-021-02039-2. Epub 2021 Oct 28. PMID: 34711954.
Copy Download .nbib Format: NLM
Oligonucleotidic therapeutics.

Expert opinion on drug discovery

Isaka Y, Imai E, Takahara S, Rakugi H.
PMID: 23506175
Expert Opin Drug Discov. 2008 Sep;3(9):991-6. doi: 10.1517/17460441.3.9.991.

Numerous oligonucleotide-based biopharmaceuticals have been tested to suppress disease progression. These potent therapeutics include plasmids containing transgenes, antisense oligonucleotides, ribozymes, DNAzymes, decoys, aptamers and small interfering RNAs. This perspective discusses the mechanisms and clinical applications of such oligonucleotidic therapeutics....

Cite
Isaka Y, Imai E, Takahara S, et al. Oligonucleotidic therapeutics. Expert Opin Drug Discov. 2008;3(9):991-6doi: 10.1517/17460441.3.9.991.
Isaka, Y., Imai, E., Takahara, S., & Rakugi, H. (2008). Oligonucleotidic therapeutics. Expert opinion on drug discovery, 3(9), 991-6. https://doi.org/10.1517/17460441.3.9.991
Isaka, Yoshitaka, et al. "Oligonucleotidic therapeutics." Expert opinion on drug discovery vol. 3,9 (2008): 991-6. doi: https://doi.org/10.1517/17460441.3.9.991
Isaka Y, Imai E, Takahara S, Rakugi H. Oligonucleotidic therapeutics. Expert Opin Drug Discov. 2008 Sep;3(9):991-6. doi: 10.1517/17460441.3.9.991. PMID: 23506175.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries